Coulter Partners successfully led a search assignment for Concept Life Sciences and is pleased to announce the placement of Dr. Adam Davenport as Chief Scientific Officer (CSO).

Concept Life Sciences is a leading global contract research organization (CRO) specializing in integrated drug discovery, development, and analytical services. The company provides consultative and collaborative solutions that enable biotech and pharmaceutical partners to navigate the complexities of translating innovations into viable therapeutics.

As CSO, Dr. Davenport will spearhead the company’s integrated drug discovery offering. A seasoned "drug hunter" with over 25 years of experience, he brings an exceptional track record of moving complex programs from initial concept through to clinical evaluation. His appointment reinforces the company’s commitment to providing world-class scientific leadership to its global collaborators.

Jonathan Critchley, interim CEO of Concept Life Sciences, commented: “We are delighted to welcome Adam to the team. His passion for science, track record in delivering clinical quality assets, and proven ability to lead multi-disciplinary teams across the UK, Europe, and the US - will be invaluable as we continue to expand our integrated discovery facilities and deliver valuable inflection points for our global clients.

“We appreciated the close partnership with Coulter Partners throughout this critical search. Their team demonstrated a deep understanding of the high-level scientific leadership required to drive our strategy, and their global reach was instrumental in securing a leader of Adam’s standing,” he continued.

Kay Wardle, Managing Partner at Coulter Partners, added: “It has been a privilege to partner with the team at Concept Life Sciences to secure such a distinguished scientific leader. Adam’s deep expertise across innovative modalities – including targeted protein degradation and covalent drug discovery – makes him the perfect fit to drive the company’s mission forward. We are proud to support Concept Life Sciences as the organization takes the next step in its journey to become a leading fully integrated CRO.”

---

Dr. Adam Davenport, CSO Concept Life Sciences

Dr. Adam Davenport brings more than 25 years of global drug discovery leadership experience across biotech and CRO environments. Prior to joining Concept Life Sciences, he served as Chief Discovery Officer at Proxygen GmbH and Chief R&D Officer at Dalriada Drug Discovery, leading oncology-focused targeted protein degradation programs and building high-impact discovery capabilities.

Previously, Adam spent over two decades at Evotec, progressing multiple programs from discovery to clinical evaluation across diverse modalities and therapeutic areas. He is the lead inventor of several Phase 2 clinical assets and has authored more than 60 patents and scientific publications. Adam holds a BSc (Hons) in Chemistry and a PhD in Organometallic Chemistry from the University of Leicester, UK.

About Concept Life Sciences

Concept Life Sciences is a leading contract research organisation (CRO) serving the global life sciences industry. For over 25 years, Concept Life Sciences, and its heritage companies, have provided consultative, and collaborative, drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables us to overcome complex scientific challenges across a broad range of therapeutic areas, improving success rates for translating innovations into viable therapeutics. To date, Concept Life Sciences has successfully helped 29 candidates advance to the clinic.
The company offers sophisticated translational biology services coupled with exceptional end-to-end chemistry capabilities offering concept to clinic solutions. Across modalities, including small molecules, biologics, peptides, and cell & gene therapies, Concept Life Sciences seamlessly integrates capabilities and provides bespoke solutions to address drug discovery challenges.
Collectively, the company’s high-quality services across the drug discovery and development pathway have helped its customers advance their drugs from concept to clinic in as little as 32 months, well ahead of the industry average of 60 months.
Driven by a passion for science, Concept Life Sciences has around 230 employees, with over 70% holding PhDs. The company operates from state-of-the-art UK facilities, headquartered near Manchester, with additional specialist operations in Edinburgh, Dundee, and Sandwich.

For more information: www.conceptlifesciences.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com

Coulter Partners places renowned scientific leader Dr. Adam Davenport as CSO at Concept Life Sciences

About Concept Life Sciences

About Coulter Partners

Related

Harley Street Healthtech Pioneer Award 2026

Building leadership for the global ecosystem: our Swiss roadshow

Nona Footz reappointed to the AESC Americas Council

The Health & Tech Collective: accelerating global innovation through strategic collaboration